The international personal care industry is undergoing a paradigm shift from symptomatic hair cosmetic solutions to follicular cell biology and scalp barrier restoration. Modern consumers treat the scalp with the same ingredient-conscious sophistication previously reserved for facial skincare. As a premier CE-compliant manufacturer based in Guangzhou with 17 years of OEM/ODM formulation excellence, Cairas Beauty provides end-to-end contract manufacturing, bulk export, and private label execution designed to satisfy the rigorous compliance criteria of the European Cosmetics Regulation (EC) No 1223/2009, US MoCRA, and ASEAN cosmetic directives.
Engineered under pharmaceutical GMP standards and verified by third-party testing for active bioavailability and microbial safety.
Modern scalp therapy bypasses superficial styling coats, focusing directly on the dermal papilla, the perifollicular vasculature, and microbiome equilibrium.
Scalp disorders such as stubborn seborrheic dermatitis, dandruff, and micro-inflammation stem from dysbiosis between Cutibacterium acnes and Malassezia restricta. Cairas formulates using postbiotic ferment filtrates, zinc PCA, and bio-fermented piroctone olamine. This strategy curtails lipid peroxidation without disrupting the natural stratum corneum barrier lipids.
Polydeoxyribonucleotide (PDRN) derived from salmon DNA stimulates A2A adenosine receptors, accelerating capillary angiogenesis and extracellular matrix regeneration around weakened follicles. Integrated with Copper Tripeptide-1, Acetyl Tetrapeptide-3, and Biotinoyl Tripeptide-1, our serums stimulate anagen phase elongation while downregulating 5α-reductase expression.
The scalp stratum corneum is dense and densely populated with sebaceous glands, posing a physical barrier to water-soluble compounds. Our laboratory deploys sub-100nm phospholipid vesicular encapsulation. This ensures active botanical terpenes, caffeine, and panthenol penetrate into the follicular infundibulum rather than evaporating on hair shafts.
Engineered specifically for cosmetic brand owners, retail distributors, and trichology clinics requiring documented efficacy.
| Parameter / Quality Index | Follicle Density Stimulating Serum | Clarifying BHA Pre-Cleanse Elixir | Microbiome Barrier Soothing Serum |
|---|---|---|---|
| Core Target Mechanism | 5α-Reductase Blockade & Microcirculation | Hyperkeratinization & Sebum Plug Cleansing | Neuro-Sensory Redness & Anti-Itch Relief |
| Hero Functional Actives | Rosemary 1,8-Cineole, PDRN, Biotinoyl Tripeptide | 2.0% Salicylic Acid, Willow Bark, Zinc Lactate | Centella Asiatica (Madecassoside), D-Panthenol 5% |
| Viscosity Profile (25°C) | 1,200 – 2,500 mPa·s (Ultra-light fluid) | 500 – 1,000 mPa·s (Aqueous sprayable) | 3,000 – 4,500 mPa·s (Hydro-gel serum) |
| Target Scalp pH (25°C) | 5.20 – 5.60 (Physiological balance) | 3.80 – 4.20 (Optimum keratolytic range) | 5.50 – 5.80 (Non-stinging barrier buffer) |
| Microbial Challenge (ISO 11930) | Passed <10 CFU/g, Zero Pathogens | Passed <10 CFU/g, Zero Pathogens | Passed <10 CFU/g, Zero Pathogens |
| Standard Export Packaging | 30ml/50ml Amber Dropper or Pipette Pen | 60ml Needle-nose Applicator Bottle | 50ml Airless Precision Tip Pump |
B2B beauty procurement is accelerating toward clean clinical integrity, digital supply chain verification, and regulatory convergence.
Procurement teams are eliminating traditional heavy silicones (dimethicone, cyclopentasiloxane) in favor of lightweight bio-esters, fermented olive squalane, and multi-molecular weight hyaluronic acid. Buyers demand clinical trial substantiation showing transepidermal water loss (TEWL) reduction directly on the scalp scalp dermis.
Under tightening global rules, cross-border brands require suppliers with accredited Cosmetic Product Safety Reports (CPSR) signed by licensed European toxicologists. Traceability documentation including allergen breakdowns, heavy metal assays (lead, arsenic, mercury), and non-animal testing proof is mandatory for customs clearance.
Enterprise brands and fast-growing digital direct-to-consumer (DTC) players increasingly demand flexible MOQ structures. Suppliers who offer ready-to-brand base formulas starting from small pilot batches (as low as 10 to 500 units) alongside seamless full-scale automated output (up to 100,000 units/day) are capturing disproportionate market share.
Established in 2009, Cairas operates a purpose-built 12,180 m² production base in Guangzhou, Guangdong, China. Verified onsite by Intertek, our automated workshops maintain comprehensive GMP, ISO 9001, and ISO 22716 certifications. We operate in-house vacuum homogenizers, high-precision automated filling systems, lyophilized powder cleanrooms, and advanced quality analysis facilities.
Every production batch undergoes dual validation: continuous inline monitoring of temperature and vacuum during emulsification, followed by rigorous QC lot release testing (Abbe refractometer purity, Brookfield viscosity, high-speed centrifuge emulsion stability, and 72-hour incubator microbial enumeration).
Addressing critical questions regarding batch release, EU/US import regulations, stability protocols, and private label execution.
For European Union importation, our regulatory department supplies a comprehensive Product Information File (PIF). This file includes a full Cosmetic Product Safety Report (CPSR Part A & B) evaluated by an accredited safety assessor, Certificate of Analysis (COA) per batch, Safety Data Sheet (SDS/MSDS) compliant with REACH Regulation (EC) No 1907/2006, 12-week accelerated stability and compatibility study results, preservative challenge test data (ISO 11930), and toxicological risk profiles of all raw materials. We also assist your designated EU Responsible Person (RP) in completing the Cosmetic Products Notification Portal (CPNP) submission.
Our operational model accommodates diverse brand maturity stages. For in-stock, pre-tested formulas (such as our Rosemary-Castor Scalp Growth Oil, 2% Salicylic Acid Scalp Serum, or Multi-Peptide Hair Density Elixirs) in standardized in-stock packaging, MOQ begins at just 3 to 10 units for pilot market tests. For customized private label branding using standard bottle libraries, MOQ ranges between 500 and 1,000 units. Completely bespoke custom chemical synthesis, unique custom-molded glass or dropper packaging, or proprietary aroma profiling typically starts at 2,000 to 5,000 units.
Sensitive actives like Salmon DNA (PDRN), oligopeptides, and volatile plant extracts are preserved through our multi-phase vacuum emulsification technology operating below 40°C during cold-active phase introduction. We integrate synergistic anti-oxidant matrices (Tocopherol, Sodium Phytate, and Ascorbyl Palmitate) and deploy nitrogen-purged filling heads. Furthermore, we provide specialized primary packaging including amber glass droppers with UV-filtering coatings, airless piston pumps, and aluminum barrier tubes that prevent oxygen and photolytic degradation.
Every lot undergoes six mandatory analytical release stages:
Yes. Trichological consumer experience relies heavily on rapid, residue-free drying without leaving hair roots greasy or stiff. Our R&D chemists utilize ultralight volatile plant alkanes, natural fermented propanediol, and modified starch sebum absorbers. We can calibrate sensory sensations from subtle neuro-cooling (using pharmaceutical-grade menthyl lactate or USP menthol) to soothing warmth (using vanillyl butyl ether) to stimulate localized cutaneous microcirculation.
We provide full multimodal export capability across FOB (Guangzhou, Shenzhen, Hong Kong), EXW, CFR, CIF, CIP, FCA, and turnkey DDP (Delivered Duty Paid, including customs clearance and door-to-door delivery across North America, Europe, Oceania, and Southeast Asia). Supported payment mechanisms include T/T (Telegraphic Transfer), Irrevocable L/C at sight, PayPal, Western Union, and secure Alibaba Escrow across major international trade currencies (USD, EUR, GBP, AUD, CAD, JPY, HKD, and CNY).
Partner with an accredited manufacturer capable of scaling your brand with clinical precision, uncompromised safety data, and international regulatory readiness.